GLP‑1 medicines can improve health and are worth their price, but many insurance plans still block them. Scientists at the University of Mississippi are studying why these limits exist and what they mean for patients.
The Institute for Clinical and Economic Review (ICER) found that drugs such as Ozempic, Wegovy, and Zepbound are cost‑effective. That means the health gains they provide are big enough to justify the cost.
Cost‑Effective Does Not Equal Cheap
Professor Sujith Ramachandran says a treatment can be valuable for society but still expensive for insurers. He explains that the large number of people who could use GLP‑1 drugs makes the total budget impact huge.
About 40% of Americans are obese, according to the CDC. Even a small share of that group using GLP‑1 drugs would add billions of dollars to insurance spending.
ICER sets a budget‑impact threshold of $821 million for this year. GLP‑1 use exceeds that limit, even when only a few people start the therapy.
Long‑Term Savings Are Still Unclear
Supporters claim early obesity treatment could cut future medical costs. However, current data do not yet show real savings from GLP‑1 use.
Many patients stop the medication within a year because of cost, reached weight goals, or stomach side effects. When they quit, they often regain the lost weight.
Insurers might see lasting savings only if patients keep the weight off. That may need coverage longer than the typical six‑month or one‑year limit, plus lifestyle help similar to clinical trials.
Medication Needs Lifestyle Support
Clinical trials compared GLP‑1 drugs plus lifestyle changes to lifestyle changes alone. This means patients need more than a weekly injection; they need diet advice, exercise options, and coaching.
Providing access to a registered dietitian, a gym membership, or a fitness instructor can help turn medication benefits into lasting habits.
Risks of Compounded GLP‑1 Products
When insurance does not cover brand‑name GLP‑1 drugs, cheaper compounded versions may appear. These products are not reviewed by the FDA and can be unsafe.
Researcher Liang‑Yuan Lin notes that the FDA has issued warnings about compounded GLP‑1 drugs that contain wrong or unapproved ingredients. Even if the label looks correct, the source and handling of the ingredients are unknown.
Patients should talk to a doctor before starting any GLP‑1 therapy and stay under medical supervision. Doctors can manage side effects, check safety, and confirm the medication is FDA‑approved.
Coverage May Shift
Some insurers are expanding coverage for specific conditions like sleep apnea, diabetes, or very high body‑mass index. At the same time, they may tighten rules for other uses.
Ramachandran warns that relying on compounded pharmacies is risky. The lower price often comes with uncertain quality and unknown ingredients.